Dialysis News and Research

Latest Dialysis News and Research

Xcorporeal signs asset purchase agreement with National Quality Care and Fresenius USA

Xcorporeal, Inc. (the “Company” or “Xcorporeal”) announced today that on December 14, 2009 it signed an asset purchase agreement (the “Purchase Agreement”) with National Quality Care, Inc. (“NQCI”, and together with the Company, the “Sellers”), and Fresenius USA, Inc. (the “Purchaser”), a Massachusetts corporation and a wholly owned subsidiary of Fresenius Medical Care Holdings, Inc., to sell substantially all of the assets of the Sellers to the Purchaser for an aggregate cash purchase price of $8,000,000 (the “Purchase Price”) and certain additional royalty payment rights.

18 Dec 2009

Initial data from REVLIMID Phase III trial in multiple myeloma patients announced

Celgene Corporation today announced the National Cancer Institute (NCI), a part of the National Institutes of Health, reported initial data from a Phase III, randomized, double-blind, multi-center clinical study led by the Cancer and Leukemia Group B (CALGB).

18 Dec 2009

Acute kidney injury associated with increased long-term mortality

Patients with sudden loss of kidney function, called acute kidney injury (AKI), are more likely to die prematurely after leaving the hospital—even if their kidney function has apparently recovered, according to an upcoming study inJournal of the American Society of Nephrology (JASN).

18 Dec 2009

Healthcare sector achieves modest revenue growth in 2008

Health care sector revenue increased by 5.7 percent in 2008 to $1.75 trillion, up from $1.66 trillion in 2007, according to new data from the U.S. Census Bureau. This sector is classified under the North American Industry Classification System as NAICS 62.

17 Dec 2009

New licensing agreement to develop and commercialize prophylactic vaccine against MRSA signed

Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, announced today that it has entered into an exclusive, world-wide licensing agreement with Syntiron to develop and commercialize its prophylactic vaccine against Staphylococcus, including Methicillin-Resistant Staphylococcus aureus or MRSA.

17 Dec 2009

Researchers identify genetic markers to help treat chronic kidney disease among diabetics

Researchers using a DNA analysis tool developed by the Translational Genomics Research Institute (TGen) and UCLA have identified genetic markers that could help treat chronic kidney disease among diabetics.

17 Dec 2009

Immigrants lose lawsuit against hospital in Atlanta

"Efforts to force the public hospital [in Atlanta, Ga.] to continue providing free dialysis treatment to a group of immigrants, most of them illegal, suffered a setback on Tuesday when a judge dismissed a lawsuit challenging the recent closing of the hospital's outpatient renal clinic," The New York Times reports.

16 Dec 2009

First Edition: December 16, 2009

Kaiser Health News staff writer Mary Agnes Carey explores some of the key issues within current health reform proposals related to Medicare and cost. "In an effort to rein in health costs, Senate Democrats are proposing steps that would give federal agencies more power to overhaul how Medicare pays for medical care - and thus reduce Congress' own role in running the giant program for the elderly" (Kaiser Health News).

16 Dec 2009

New York Times highlights shortfalls in transplant patient immunosuppressive drug coverage

Today's New York Times article by Kevin Sack, "Plan for Kidney Drugs Spurs Division," illustrates an internal renal community reimbursement debate that may result in kidney patients continuing to be deprived of their life-saving immunosuppressive medications beyond the current 36-month Medicare program limit.

16 Dec 2009

Kidney drug plan divides transplant and dialysis supporters

The New York Times: "A Congressional proposal to help pay for drugs needed by transplant recipients to prevent rejection of donated kidneys has run into opposition from dialysis providers, drug companies and the National Kidney Foundation." The groups support extending Medicare drug coverage but say the measure would cut funding for dialysis

15 Dec 2009

First Edition: December 15, 2009

A glance at today's health policy headlines offers a common theme: Senate Democrats are likely to abandon the Medicare buy-in plan, which just last week was heralded as part of a compromise plan in that chamber's health bill.

15 Dec 2009

Majority of dialysis patients face readmission to acute care facilities, says study

A new study by University of Cincinnati (UC) nephrologists shows that most dialysis patients admitted to long-term care hospitals face readmission to acute care facilities, and those with acute kidney failure don't often recover full kidney function.

15 Dec 2009

Researchers to receive more than $4.5 million in grants to study Sudden Infant Death Syndrome

Researchers at the Los Angeles Biomedical Research Institute (LA BioMed) expect to receive more than $4.5 million in grants from the American Recovery and Reinvestment Act (Recovery Act.), including nearly $1 million from the highly competitive Challenge Grant program for a study that seeks to reduce the number of children who die from Sudden Infant Death Syndrome, it was announced today.

15 Dec 2009

ARKRAY's Assure Platinum Blood Glucose Monitoring System receives FDA clearance

ARKRAY, Inc., the world's 5th largest manufacturer of diabetes self-monitoring systems, today received FDA clearance on the new Assure Platinum Blood Glucose Monitoring System.

10 Dec 2009

Misuse of blood thinners in dialysis patients reported

Reuters/ABC News reports on research published in the Journal of the American Medical Association that examined the misuse of two blood thinners - Lovenox and Integrilin - in "about 20 percent of kidney dialysis patients who undergo a procedure to open a blocked artery [who] are given the wrong blood clot medicine, increasing the chances of significant bleeding, researchers said Tuesday.

9 Dec 2009

Data evaluating combination therapy with REVLIMID and rituximab in patients with NHL presented

Celgene International Sàrl announced that investigational data evaluating combination therapy with REVLIMID (lenalidomide) and rituximab in patients with indolent non-Hodgkin’s lymphoma (NHL) were presented during the 51st American Society of Hematology’s annual meeting in New Orleans, LA.

9 Dec 2009

Antithrombotic medication may increase risk of bleeding in dialysis patients undergoing PCI procedure

Approximately 20 percent of dialysis patients undergoing a percutaneous coronary intervention (PCI; procedure such as angioplasty) are given an antithrombotic medication they should not receive, which may increase their risk for in-hospital bleeding, according to a study in the December 9 issue of JAMA.

9 Dec 2009

Study data of REVLIMID-dexamethasone combination therapy for high-risk smoldering multiple myeloma

Celgene International Sàrl announced that data evaluating combination therapy REVLIMID (lenalidomide) and dexamethasone in patients with high-risk smoldering multiple myeloma were presented during the American Society of Hematology’s annual meeting in New Orleans, LA. The landmark study demonstrated REVLIMID and dexamethasone prolonged time to progression, including complete responses, with manageable toxicity.

8 Dec 2009

Gentium presents evaluation results of Defibrotide for VOD at the ASH conference

Gentium S.p.A. today announced final clinical trial results from the Company’s Phase II/III Pediatric Prevention trial and Phase III Treatment trial for Defibrotide of Hepatic Veno-Occlusive Disease (VOD), which were presented at the American Society of Hematology Conference (ASH) in New Orleans.

8 Dec 2009

Study results comparing REVLIMID regimen to stem cell transplant in multiple myeloma patients

Celgene International Sàrl announced clinical data from an investigational study of patients with multiple myeloma who were younger than 65 years old and received either REVLIMID (lenalidomide), melphalan and prednisone (MPR) or melphalan plus autologous stem cell transplant (MEL200) following an induction treatment of REVLIMID plus low-dose dexamethasone (Rd) were presented during the 51st American Society of Hematology’s annual meeting in New Orleans, LA.

8 Dec 2009

Dialysis News and Research

Latest Dialysis News and Research

Xcorporeal signs asset purchase agreement with National Quality Care and Fresenius USA

Initial data from REVLIMID Phase III trial in multiple myeloma patients announced

Acute kidney injury associated with increased long-term mortality

Healthcare sector achieves modest revenue growth in 2008

New licensing agreement to develop and commercialize prophylactic vaccine against MRSA signed

Researchers identify genetic markers to help treat chronic kidney disease among diabetics

Immigrants lose lawsuit against hospital in Atlanta

First Edition: December 16, 2009

New York Times highlights shortfalls in transplant patient immunosuppressive drug coverage

Kidney drug plan divides transplant and dialysis supporters

First Edition: December 15, 2009

Majority of dialysis patients face readmission to acute care facilities, says study

Researchers to receive more than $4.5 million in grants to study Sudden Infant Death Syndrome

ARKRAY's Assure Platinum Blood Glucose Monitoring System receives FDA clearance

Misuse of blood thinners in dialysis patients reported

Data evaluating combination therapy with REVLIMID and rituximab in patients with NHL presented

Antithrombotic medication may increase risk of bleeding in dialysis patients undergoing PCI procedure

Study data of REVLIMID-dexamethasone combination therapy for high-risk smoldering multiple myeloma

Gentium presents evaluation results of Defibrotide for VOD at the ASH conference

Study results comparing REVLIMID regimen to stem cell transplant in multiple myeloma patients

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Dialysis News and Research

Latest Dialysis News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in